Cytomed Therapeutics announces publication of research on T cells

CytoMed Therapeutics (GDTC) announces the publication of a preclinical study, in a research article entitled “Donor-Derived Vgamma9Vdelta2 T Cells for Acute Myeloid Leukemia: A Promising “off-the-shelf” Immunotherapy Approach”. The study results from this collaborative research with The University of Texas, MD Anderson Cancer Center, MDACC, are suggesting the promising potential of CytoMed’s allogeneic gammadelta T cell therapy, CTM-GDT, for treating acute myeloid leukemia, AML. This collaboration with MDACC is under a previously announced research agreement in May 2023. The research article is now publicly and freely online at Donor-Derived Vgamma9Vdelta2 T Cells for Acute Myeloid Leukemia: A Promising “Off-the-Shelf” Immunotherapy Approach.